Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$5 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.3
Industry P/E
--
EV/EBITDA
-3.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
1,639,520
CFO
$-417.82 Mln
EBITDA
$-659.71 Mln
Net Profit
$-831.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alaunos Therapeutics (TCRT)
| 48.1 | 12.4 | 74.1 | -78.0 | -68.3 | -62.9 | -46.2 |
|
BSE Sensex
| 5.5 | 9.8 | 8.7 | 12.9 | 16.1 | 21.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
Alaunos Therapeutics (TCRT)
| -81.6 | -89.2 |
|
S&P Small-Cap 600
| 7.0 | 13.9 |
|
BSE Sensex
| 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Alaunos Therapeutics (TCRT)
|
2.8 | 4.7 | 0.0 | -3.7 | -31,341.7 | -156.3 | -- | 2.3 |
| 99.4 | 6,419.8 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 18.8 | |
| 55.5 | 10,124.2 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.1 | |
| 40.2 | 5,161.2 | 774.0 | -416.6 | -53.5 | -- | -- | 55.7 | |
| 49.2 | 8,204.1 | 1,084.3 | 485.4 | 43.3 | 103.8 | 17.7 | 16.8 | |
| 287.5 | 6,558.0 | 317.4 | -391.6 | -118.9 | -52.6 | -- | 9.2 | |
| 299.1 | 8,914.2 | 2,156.6 | 416.4 | 15.6 | 56.5 | 23.7 | 15.2 | |
| 23.8 | 9,858.1 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 0.9 | |
| 118.5 | 11,566.1 | 2,412.6 | 305.8 | 20.5 | 11.6 | 39.6 | 4.5 | |
| 35.6 | 3,557.6 | 2,233.4 | -248.4 | 9.6 | -21 | -- | 3.1 |
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1... receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas. Address: 2617 Bissonnet Street, Houston, TX, United States, 77005 Read more
Interim CEO & Director
Mr. Dale Curtis Hogue Jr.
Interim CEO & Director
Mr. Dale Curtis Hogue Jr.
Headquarters
Houston, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Alaunos Therapeutics Inc (TCRT) stood at $ 6 Mln as on 31-Mar-25
The share price of Alaunos Therapeutics Inc (TCRT) is $2.82 (NASDAQ) as of 15-May-2025 11:58 EDT. Alaunos Therapeutics Inc (TCRT) has given a return of -68.29% in the last 3 years.
Alaunos Therapeutics Inc (TCRT) has a market capitalisation of $ 5 Mln as on 14-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Alaunos Therapeutics Inc (TCRT) is 2.29 times as on 14-May-2025, a 7% premium to its peers’ median range of 2.15 times.
Since, TTM earnings of Alaunos Therapeutics Inc (TCRT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Alaunos Therapeutics Inc (TCRT) and enter the required number of quantities and click on buy to purchase the shares of Alaunos Therapeutics Inc (TCRT).
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas. Address: 2617 Bissonnet Street, Houston, TX, United States, 77005
The CEO & director of Mr. Dale Curtis Hogue Jr.. is Alaunos Therapeutics Inc (TCRT), and CFO & Sr. VP is Mr. Dale Curtis Hogue Jr..
There is no promoter pledging in Alaunos Therapeutics Inc (TCRT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,086
|
|
|
1,077
|
|
|
1,006
|
|
|
864
|
|
|
756
|
|
|
680
|
|
|
658
|
|
|
626
|
|
|
546
|
| Alaunos Therapeutics Inc. (TCRT) | Ratios |
|---|---|
|
Return on equity(%)
|
-156.26
|
|
Operating margin(%)
|
-31341.67
|
|
Net Margin(%)
|
-31166.67
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Alaunos Therapeutics Inc (TCRT) was $0 Mln.
$-0.07
(
